Clinical Trial Results:
A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen® given every 6 weeks for up to 102 weeks, plus sham photodynamic therapy (PDT) to Macugen® plus PDT with Visudyne® in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD).
Summary
|
|
EudraCT number |
2004-004867-31 |
Trial protocol |
GB SE AT DE IT ES |
Global completion date |
31 Mar 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Dec 2016
|
First version publication date |
28 Dec 2016
|
Other versions |
|
Summary report(s) |
A5751012 Public Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.